Well, phase I was announced last year. We were approached by the NRC for our phase II trial. We've had really good dialogue ever since phase I started. That process has gone on. That started probably about two months ago, as we geared up to conclude our phase I trial and release data. Although the NRC is capped at $10 million, which is certainly not sufficient to carry out phase II and phase III trials, the NRC has, through the bureaucracy, elevated us back up to the strategic innovation fund. That occurred about three weeks ago. We're now working with the strategic innovation fund.
Would I like it to go faster? Yes, but it's still progressing, and I believe that it will continue to progress and that we'll get the support we need for our clinical trials.
Part of the challenge we have, to communicate specific challenges, is the need of comparator vaccines. That was communicated last week to the finance committee. I've communicated it to multiple departments within Canada. I'm still awaiting a response—